Sandra Horning, M.D., 77 Director since: 2020 2025 Attendance: 100% Committees Product and Technology (Chair) Nominating and Corporate Governance Education M.D. from the University of Iowa School of Medicine Completed internal medicine training at the University of Rochester Post-graduate fellowship in Oncology and Cancer Biology at Stanford University Why this director is valuable to Moderna Dr. Horning brings decades of experience in the healthcare industry to the Board as a practicing oncologist and investigator, professor of medicine, and an executive leading pharmaceutical drug development with 15 new medicine approvals across a variety of disease areas, including in oncology. Dr. Horning provides valuable insight to our research and development teams as they develop products across our portfolio. She has advanced multiple novel oncology product candidates successfully through regulatory approval and ultimately to patients worldwide. These insights inform how we progress clinical development, engage with regulators and stakeholders, and prepare for commercialization of our product pipeline. Dr. Horning s experience as an executive and director at other healthcare companies also informs our understanding of healthcare industry dynamics and our governance practices. Other Public Boards Revolution Medicines, Inc. (since 2023) Gilead Sciences, Inc. (since 2020) Olema Pharmaceuticals, Inc. (since 2020) EQRx, Inc. (2021-2023) Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2014 until her retirement in 2019, and, prior to that, served as Global Head of Oncology Clinical Science at Roche from 2009 to 2013. Prior to Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured Professor of Medicine at Stanford University School of Medicine, where she remains a Professor of Medicine Emerita. From 2005 to 2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors.